Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brostallicin in Platinum-Pretreated NSCLC
NCT00034957Phase 2Completed
- Sponsor
- Pfizer
- Primary completion
- Oct 2002
- Modality
- DNA Intercalators/Alkylators, Recombinant Proteins and Enzymes, Prodrugs/Conditional Activator Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of brostallicin in non-small cell lung cancer (NSCLC), sponsored by Pfizer. Primary endpoint: Efficacy of Investigational Drug. Status: completed.
02
Drugs
brostallicin
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00034957.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00034957.